Navigation Links
Neuralstem Updates ALS Clinical Trial Progress
Date:2/10/2011

ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first nine patients, the trial's Safety Monitoring Board has unanimously approved moving to the last group of ALS patients in this part of the safety trial. These next three patients, all of whom are ambulatory, will each receive ten injections, bilaterally, in the lumbar spinal cord. After this cohort, the FDA will review the trial data to date before approving it to move into the final cohort of patients, who will receive injections in the cervical region of the spinal cord.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"We are delighted that we've advanced to this final cohort of patients in the first part of the safety trial," commented Dr. Eva Feldman, PhD, MD,  Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "We have been pleased with the smooth progress of the trial thus far, from non-ambulatory to ambulatory patients who have an earlier stage of the disease."

"We are greatly encouraged by the SMB's approval to advance the trial to the final three patients to receive full lumbar injections," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "The trial has progressed as expected, and we are deeply indebted to the patients and families who have taken part."

About The Trial

The Phase I trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS, the first FDA-approved ALS stem cell trial, has been underway since January, 2010. The trial plans to enroll up to 18 ALS patients, who will be examined at regular intervals post-surgery.

All of the first six patients treated in the trial were non-ambulatory. Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord. The next three patients received ten injections each, bilaterally in the lumbar region. All remaining trial patients are ambulatory, and therefore represent earlier stages of disease progression. Of the ambulatory group, the first three patients received five injections each, unilaterally, in the lumbar region. The next three, which have just been approved, will receive ten injections each, bilaterally, in the lumbar region. After the required FDA approval, the final six patients in the trial will receive injections in the cervical region.  

While the trial is evaluating only the safety of the cells and procedure, it includes exploratory endpoints including  attenuation of motor function loss, maintenance of respiratory capacity, and stabilization of patients along the ALS functional rating scale.

The Emory ALS Center has posted the relevant trial information for patients on its website at http://www.neurology.emory.edu/ALS/Stem%20Cell.html.  

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, which has been rewarded Orphan Drug Status by the FDA.

In addition to ALS, the company is also targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has been approved to commence a Phase Ia safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depression.  Additional indications could include schizophrenia, Alzheimer's disease, traumatic brain injury, posttraumatic stress syndrome, and stroke.

For more information, please go to www.neuralstem.com.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2009, and in its quarterly report on Form 10-Q for the period ended September 30, 2010.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
2. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
3. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
4. Neuralstems ALS Trial on Clinical Hold
5. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
6. Neuralstem Announces Issuance of Core Technology Patent in Europe
7. K-V Pharmaceutical Company Updates Status of New Drug Application for Gestiva™
8. ISTA Pharmaceuticals Achieves 2010 Revenue and Earnings Guidance; Provides 2011 Financial Guidance and Updates Key Plans
9. Vista Partners Updates Coverage on Pro-Pharmaceuticals, Inc.; Maintains Target Price of $2.10
10. Access Pharmaceuticals Updates MuGard Website With First Patient Testimonial Video
11. Intercell AG Announces Q3 2010 Results and Updates on R&D Progress and Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ACME Markets, Delaware County ... Councilman Dave White announced today the availability ... pharmacies across Delaware County . According ... has saved 26,463 lives nationwide over the past 20 years. Since ... were authorized to administer naloxone to overdose victims, 244 lives ...
(Date:5/3/2016)... May 3, 2016   Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it is celebrating ... video of two patients who tell their personal story and encourage those at risk to ... Meet Jacque: Hepatitis C ... ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... 2016 Intec Pharma Ltd. (NASDAQ: ... company, today announced the appointment of Pnina Strauss-Levy ... "Ms. Strauss-Levy has 15 years of experience in ... outstanding track record, having supported the advancement of several ... in the United States and ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... ... operators of commercial real estate proudly announced that its service-based charitable program, Olshan ... Team members portfolio-wide will continue Olshan Properties’ annual philanthropic tradition in 2016 with ...
(Date:5/4/2016)... ... 04, 2016 , ... A new collaboration will give more researchers access to ... (DCRI) and analytics leader SAS will provide researchers worldwide with data management and analytics ... Health System. , The DCRI and SAS share the goal of greater transparency ...
(Date:5/4/2016)... ... ... May kicked off with Melanoma Monday , a multi-agency effort to raise ... encouraging her patients, as well as residents all around Dallas, Cleburne, Irving, and Plano, ... in the future. , The dermatology-specific awareness month ends with “Don’t Fry Day,” established ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... of foundational nutrients that supports cellular and metabolic health. This synergistic combination of ... mg free-form curcumin, along with 150 mg of reduced glutathione and 200 mg ...
(Date:5/4/2016)... (PRWEB) , ... May 04, 2016 , ... ... and the pharmacy industry, today announced that it was chosen as the Pharmaceutical ... (APPA) Industry Awards . The awards acknowledge the hard work and dedication of ...
Breaking Medicine News(10 mins):